Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207399 · ClinicalTrials.gov registry record · Phase 4
Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03207399 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 1 participants.
The verdict
NCT03207399, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether treatment with Epclusa (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C infection is feasible, safe and effective at curing HCV.
Interventions
- DRUG Epclusa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2019-03-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03207399
The ClinicalTrials.gov registry entry for NCT03207399 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epclusa is the first listed.
NCT03207399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03207399 about?
NCT03207399 is a clinical study titled "Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment". The purpose of this study is to evaluate whether treatment with Epclusa (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C infection is feasible, safe and effective at curing HCV.
What is the current status of trial NCT03207399?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2017-09-15. Estimated completion is 2019-03-25.
What interventions are being tested in trial NCT03207399?
The interventions under investigation include: Epclusa (DRUG).
Who is sponsoring clinical trial NCT03207399?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.